top of page
    • May 19, 2022
    • 1 min read

The Foot & Ankle Consolidation Trend Continues

On May 4, CONMED Corporation (NYSE: CNMD) announced a definitive agreement to acquire privately-held In2Bones Global, Inc. for cash consideration of $145 million at closing and up to an additional $110 million in growth-based earnout payments over a four-year period.

In2Bone, led by foot and ankle veteran Alan Taylor, had 2021 revenue of $36.8 million with sustained double-digit growth. While CONMED is a large company, including 3,500 employees, it has a small footprint in foot and ankle, making this a partnership an upside on both sides.

8 views0 comments

Recent Posts

See All

Avascular necrosis of the talus has been a diagnosis vexing foot-and-ankle surgeons for a long time. Real pain and disability with treatment options have often been lacking. Let's take a deeper look a

Cannabis sativa derivatives, or cannabinoids, are making their way into many of our pain strategies. Cannabidiol (CBD) is the most popular because of the lack of psychotropic effects. Deckey et al. fo

Motion improvement is one goal patients and surgeons can agree on with total ankle replacement. In search of dorsiflexion (DF) motion, equinus contracture is often addressed as an adjunct procedure. L

FIX Masthead 2000x318 v2.jpg
bottom of page